Summit Therapeutics Inc
NASDAQ:SMMT

  • LAST PRICE
    2.1300
  • TODAY'S CHANGE (%)
    0.1000 (4.9261%)
  • Bid / Lots
    2.0100/ 200
  • Ask / Lots
    2.1300/ 12
  • Open / Previous Close
    1.9900 / 2.0300
  • Day Range
    1.9300
    2.1400
  • 52 Week Range
    0.6600
    5.7800
  • Volume
    1,700,984

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

Charts

Price Comparison Graph. See accessible table below
Data delayed at least 15 minutes.

Biotechnology Industry Peers

CompanyMarket CapP/E Ratio (TTM)EPS Growth (5yr)
SMMT
Summit Therapeutics Inc
1.5B
-1.3x
---
RYZB
RayzeBio Inc
1.4B
-20.9x
---
IOVA
Iovance Biotherapeutics Inc
1.6B
-3.0x
---
IRON
Disc Medicine Inc
1.3B
-14.9x
---
VKTX
Viking Therapeutics Inc
1.3B
-14.1x
---
MRUS
Merus NV
1.5B
-6.8x
---
As of 2023-12-02

Company Information

Summit Therapeutics Inc. is a biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The Company is engaged in research and development activities, primarily comprising oncology product research activities (including ivonescimab), and anti-infectives program activities. Ivonescimab, is a novel, potential first-in-class bispecific antibody intending to combine the benefits of immunotherapy via a blockade of PD-1 with the anti-angiogenesis benefits of an anti-VEGF into a single molecule. The Company’s preclinical candidate, SMT-738, from the DDS-04 series for development in the fight against multi-drug resistant infections, specifically Carbapenem-resistant Enterobacteriaceae (CRE) infections. It owns a genetics platform and a suite of software-based technologies (Discuva Platform).

Contact Information

Headquarters
2882 Sand Hill Road, Suite 106MENLO PARK, CA, United States 94025
Phone
617-514-7149
Fax
302-655-5049

Executives

Executive Chairman of the Board, Co-Chief Executive Officer
Robert Duggan
President, Co-Chief Executive Officer, Director
Mahkam Zanganeh
Chief Financial Officer
Ankur Dhingra
Lead Non-Executive Director
Manmeet Soni
Non-Executive Director
Yu Xia

Ratings

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Reports

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals

Market Cap
$1.5B
Revenue (TTM)
$0.00
Shares Outstanding
700.8M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
-1.16
EPS
$-1.59
Book Value
$0.60
P/E Ratio
-1.3x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Calendar

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.